|
|
Article: India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013.
- Article from:
- PR Newswire
- Article date:
- May 13, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources
WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate ...